The PLAC test is used to determine Lp-PLA2 in serum or plasma.
Lp-PLA2 stands for Lipoprotein-Associated Phospholipase A2.
The test is used to determine your cardiovascular risk disease, myocardial infarction and ischemic stroke associated with atherosclerosis. In recent years, a number of studies have been published pointing to Lp-PLA2 as a marker for determining cardiovascular risk.
Lp-PLA2 activity is to be used in conjunction with clinical evaluation and a risk assessment as an aid in predicting risk of coronary heart disease (CHD) in people with no prior history of cardiovascular events.
Lp-PLA2 is a calcium-independent phospholipase A2 enzyme that is associated with both low-density lipoprotein (LDL) and, to a lesser extent, high-density lipoprotein (HDL) in human plasma and serum and is distinct from other such phospholipases such as cPLA2 and sPLA2.2,3 Lp-PLA2 is produced by macrophages and other inflammatory cells and is expressed in greater concentrations in advanced atherosclerotic lesions than early-stage lesions.
Several lines of evidence suggest that oxidation of LDL plays a critical step in the development and progression of atherosclerosis.
Lp-PLA2 participates in the breakdown of oxidized LDL in the vascular wall by hydrolyzing the oxidized phospholipid, producing lysophosphatidylcholine and oxidized free fatty acids, both of which are potent pro-inflammatory products that contribute to the formation of atherosclerotic plaques.
Lp-PLA2 has demonstrated modest intra- and inter-individual variation, commensurate with other cardiovascular lipid markers and substantially less variability than high sensitivity C-reactive protein (hs-CRP). In addition, Lp-PLA2 is not elevated in systemic inflammatory conditions, and may be a more specific marker of vascular inflammation. The relatively small biological variation of Lp-PLA2 and its vascular specificity are of value in the detection and monitoring of cardiovascular risk.
- Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005 May;25(5):923-931. PubMed 15731492
- Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:3-58. PubMed 12432908
- Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res. 2009 Apr;50:s237-242. PubMed 19011112
- Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2909-2917. PubMed 10591668
- Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2523-2529. PubMed 16960105
- Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994 Sep;344(8925):793-795. PubMed 7916078
- Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000 Jun 15;28(12):1815-1826. PubMed 10946223
- Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999 Mar 1;338(Pt 2):479-487. PubMed 10024526
- Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001 Apr;1(2):121-125. PubMed 11714085
- Suckling KE, Macphee CH. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin Ther Targets. 2002 Jun;6(3):309-314. PubMed 12223071
- Wolfert RL, Kim NW, Selby RG, Sarno MJ, Warnick GR, Sudhir K. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA), a novel marker of cardiovascular risk (abstract). Circulation. 2004;110(Supplement 3):309.
- Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol. 2008 Jun 16;101(12A):11F-22F. PubMed 18549867
- Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 1;375(9725):1536-1544. PubMed 20435228
Understand and improve your laboratory results with our health dashboard.
Upload your lab reports and get interpretation today.
Our technology helps to understand, combine, track, organize, and act on your medical lab test results.
Increased risk of CVD, CHD, and stroke.
Possible treatment options:
Statins, therapeutic lifestyle changes
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.
Interpret Your Lab Results
Upload your lab report and we’ll interpret and provide you with recomendations today.Get Started
Get Started With Our Personal Plan
Are You a Health Professional?
Get started with our professional plan
Welcome to Healthmatters Pro.
Save time on interpreting lab results with the largest database of biomarkers online. In-depth research on any test at your fingertips, all stored and tracked in one place. Learn more
for health professionals
$45 per month
Apo B : Apo A-1, Atherogenic index, Estimated CHD Risk, Glycomark (1 ,5-Anhydroglucitol), HDL-C, HDL-C/TG, hsCRP, IDL Cholesterol, LDL-C, LDL/HDL Cholesterol Ratio, Leptin : Adiponectin ratio, Non-HDL Cholesterol, Oxidized LDL : LDL-C, OxLDL (Oxidized LDL), PLAC, PLAC (LP-PLA2 Activity), Small dense LDL Cholesterol, Small dense LDL-C : LDL-C, Total Cholesterol, Total Cholesterol/HDL Ratio, Triglycerides, VLDL-C/TG